Drugs that contain Bupropion Hydrobromide
1. Aplenzin patents expiration
Can you believe APLENZIN received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572935 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7569610 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7645802 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) | |
| US7662407 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7585897 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7649019 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7241805 | BAUSCH | Modified release formulations of a bupropion salt |
Jun, 2026
(2 years from now) | |
| US7671094 | BAUSCH | Bupropion hydrobromide and therapeutic applications |
Jun, 2026
(2 years from now) | |
Market Authorisation Date: 23 April, 2008
Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of APLENZIN before it's drug patent expiration?
More Information on Dosage
APLENZIN family patents
